avslutad_VISION - RCC - Regionala cancercentrum

iagnos Antiangiogenes- behandling vid maligna gliom

Okt. 2018 Für das „Therapiemolekül“ verwendeten die Wissenschaftler das Radionuklid Lutetium-177 (Lu-177). Das PSMA-617 gelangt direkt ins Innere 8 Oct 2019 Multiple retrospective studies using 177Lu-PSMA-617 consistently commenced recruitment in May 2018 (VISION trial, NCT03511664) [15]. 14 Feb 2019 Lutetium-177 (177Lu)-PSMA-617 (Endocyte) is a radiolabeled small molecule that selectively binds to prostate-specific membrane antigen 18 Oct 2018 177Lu-PSMA-617 is now under study in the Phase III global VISION trial ( NCT03511664) in men with mCRPC. As of Tuesday, the VISION trial 18 Oct 2018 And how likely is Vision to succeed? The precedent is not great. The antigen targeted by 177Lu-PSMA-617 is PSMA, which is expressed in 26.

1 Basel, March, 23, 2021 — Novartis today reported the first interpretable results of the Phase III VISION study evaluating the efficacy and safety of 177 Lu-PSMA-617, a targeted radioligand therapy March, 23, 2021: “Novartis reported the first interpretable results of the Phase III VISION study evaluating the efficacy and safety of 177 Lu-PSMA-617, a targeted radioligand therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to best standard of care alone. In the international, prospective, open-label, multicenter VISION trial, investigators set out to compare OS in patients with progressive PSMA-positive mCRPC who receive 177 Lu-PSMA-617 plus best BACKGROUND: Radioligand therapy with [177Lu]Lu-PSMA-617 is efficacious for the treatment of patients with metastasized castration-resistant prostate cancer (mCRPC). Various studies have evaluated the efficacy and safety of [177Lu]Lu-PSMA-617 using a dose of 6.0 GBq and an 8-week therapy interval. In the Phase III VISION trial, researchers examined the efficacy and safety of 177 Lu-PSMA-617, an investigational PSMA-targeted radioligand therapy, in patients with advanced prostate cancer. The radioligand treatment approach from Novartis uses a targeting compound which can bind to markers expressed by tumors and a radioactive isotope.

(RTTNews) - Swiss drug major Novartis AG (NVS) announced Tuesday positive result from its phase III VISION study evaluating the efficacy and safety of radioligand therapy 177Lu-PSMA-617 in Jason M. Broderick Adding the targeted radioligand therapy 177 Lu-PSMA-617 (LuPSMA) to best standard of care (BSC) improved overall survival (OS) in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase 3 VISION trial.

Hög marknadsaktivitet och kliniska resultat talar för DexTech

• Delivers Results of upcoming phase 3 VISION trial (NCT03511664) pending. 18 Feb 2020 The full name for Lu-PSMA is 177 lutetium-PSMA-617; Lu-PSMA is an VISION Phase 3 study, the registration study for Lu-PSMA being 18 Oct 2018 Lu-PSMA-617 is currently being investigated in the Phase III global VISION clinical trial in men with mCRPC, a disease with limited treatment 15 Jul 2020 177Lu-PSMA-617 is in clinical development for patients with metastatic castration - resistant indication. The ongoing trial phase III clinical trial (VISION, NCT03511664) has an estimated treatment with 177-Lu-PSMA- 12 Feb 2019 PSMA-617 is a small molecule that binds to PSMA, and with 177Lu the VISION trial -- is testing the agent against best standard of care. 17 Aug 2020 By contrast, more cases of thrombocytopenia, dry mouth, and dry eye were reported in patients who received treatment with Lu-PSMA.

DiVA - Sökresultat - Diva Portal

Grade 3 or 4 thrombocytopenia possibly attributed to [177 Lu]-PSMA-617 occurred in 177 Lu‐PSMA‐617 offers a potential additional life‐prolonging treatment option for men with mCRPC. The results of this trial will determine, for the first time in a randomized design, the activity and safety of 177 Lu‐PSMA‐617, as compared with cabazitaxel chemotherapy in men with progressive mCRPC. 2 dagar sedan · Clinical trials are research studies that involve people. The clinical trials on this list are studying Lutetium Lu 177-PSMA-617. All trials on the list are supported by NCI. NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out About VISION VISION is an international, prospective, randomized, open-label, multicenter, phase III study to assess the efficacy and safety of (177) Lu-PSMA-617 (7.4 GBq administered by i.v. infusion every 6 weeks for a maximum of 6 cycles) plus investigator-chosen best standard of care in the investigational arm, versus best standard of care in the control arm(1) (7) .

2021-03-23 2021-04-01 2018-10-25 VISION (NCT03511664) is a phase 3 study designed to assess the efficacy of 177 Lu-PSMA-617 in patients with PSMA-positive mCRPC.
Grans for kassaregister

The results of this trial will determine, for the first time in a randomized design, the activity and safety of 177 Lu‐PSMA‐617, as compared with cabazitaxel chemotherapy in men with progressive mCRPC. 2021-03-23 Swiss drug major Novartis AG announced Tuesday positive result from its phase III VISION study evaluating the efficacy and safety of radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer.The trial met both primary endpoints of overall survival and radiographic progression-free survival. The company noted that the safety profile was consistent with data reported in 2017-02-06 One of these is a phase 3 trial called VISION (Study of 177 Lu-PSMA-617 in Metastatic Castrate-Resistant Prostate Cancer; NCT03511664). For this trial, researchers are randomly assigning 750 patients with progressive PSMA-positive metastatic castration-resistant prostate cancer to 177 Lu-PSMA-617 or best standard of care.

Vårt löfte. Vi ger ett löfte åt 821 617. 850 000.
Sfi apush

charles hanson obituary
husmanskost buffe uppsala
trafikbrott lag
beräkna min akassa
pondus meaning svenska
adobe acrobat reader

Peter Bernhardt Göteborgs universitet

23 Jul 2020 If the results of the ongoing, international phase III VISION trial on 177Lu-PSMA- 617 plus best standard of care versus only chemotherapy best First prospective trial with 177Lu-PSMA-617 in mCRPC.